![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 4
2022
Cristofanilli, Massimo; Rugo, Hope S.; Im, Seock-Ah; Slamon, Dennis J.; Harbeck, Nadia; Bondarenko, Igor; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela; Loi, Sherene; Iwata, Hiroji; O'Leary, Ben; Andre, Fabrice; Loibl, Sibylle; Bananis, Eustratios; Liu, Yuan; Huang, Xin; Kim, Sindy; Frean, Maria Jose Lechuga und Turner, Nicholas C.
(2022):
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2(- )ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
In: Clinical Cancer Research, Bd. 28, Nr. 16: S. 3433-3442
2018
Rugo, Hope S.; Turner, Nicholas C.; Finn, Richard S.; Joy, Anil A.; Verma, Sunil; Harbeck, Nadia; Masuda, Norikazu; Im, Seock-Ah; Huang, Xin; Kim, Sindy; Sun, Wan; Iyer, Shrividya; Schnell, Patrick; Bartlett, Cynthia Huang und Johnston, Stephen
(2018):
Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
In: European Journal of Cancer, Bd. 101: S. 123-133
2017
Loibl, Sibylle; Turner, Nicholas C.; Ro, Jungsil; Cristofanilli, Massimo; Iwata, Hiroji; Im, Seock-Ah; Masuda, Norikazu; Loi, Sherene; Andre, Fabrice; Harbeck, Nadia; Verma, Sunil; Folkerd, Elizabeth; Theall, Kathy Puyana; Hoffman, Justin; Zhang, Ke; Bartlett, Cynthia Huang und Dowsett, Mitchell
(2017):
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
In: Oncologist, Bd. 22, Nr. 9: S. 1028-1038
2016
Cristofanilli, Massimo; Turner, Nicholas C.; Bondarenko, Igor; Ro, Jungsil; Im, Seock-Ah; Masuda, Norikazu; Colleoni, Marco; DeMichele, Angela; Loi, Sherene; Verma, Sunil; Iwata, Hiroji; Harbeck, Nadia; Zhang, Ke; Theall, Kathy Puyana; Jiang, Yuqiu; Bartlett, Cynthia Huang; Koehler, Maria und Slamon, Dennis
(2016):
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
In: Lancet Oncology, Bd. 17, Nr. 4: S. 425-439